Lerociclib clinical trials
Also written G1T38.
How each study uses lerociclib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lerociclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Genor Biopharma Co., Ltd. (3) · G1 Therapeutics, Inc. (3) · EQRx International, Inc. (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses lerociclib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerRecruitingPhase 3Genor Biopharma Co., Ltd.NCT05851014Written as GB491 combined with Letrozole
- GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedPhase 3Genor Biopharma Co., Ltd.NCT05054751Written as GB491+ Fulvestrant
- Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial CancerWithdrawnPhase 3EQRx International, Inc.NCT05712941Written as Lerociclib
- G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerCompletedPhase 1/2G1 Therapeutics, Inc.NCT03455829Written as G1T38
- G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus unknownPhase 1/2G1 Therapeutics, Inc.NCT02983071Written as G1T38
- A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast CancerStatus unknownPhase 1Genor Biopharma Co., Ltd.NCT05337657Written as GB491+Letrozole
- First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy VolunteersCompletedPhase 1G1 Therapeutics, Inc.NCT02821624Written as G1T38 (CDK 4/6 Inhibitor)
Codes
What other systems call lerociclib · ClinicalTrials.gg INT018341
- UNII (FDA) WBH8AY6ENBLEROCICLIBConfirmed FDA, Wikidata
- Wikidata Q105337326lerociclibConfirmed FDA, Wikidata
- NCI Thesaurus C138165LerociclibOne source FDA
- DrugBank DB16218One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WBH8AY6ENB | LEROCICLIB | Confirmed FDA, Wikidata |
| Wikidata | Q105337326 | lerociclib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C138165 | Lerociclib | One source FDA |
| DrugBank | DB16218 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.